Sibeprenlimab

斯贝利单抗

Report date: 2026/05/06 20:02:28

Base Information

Drug NameSibeprenlimab
Drug Alias NameSibeprenlimab-SZSIVoyxactVIS-649
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 inhibitors
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsGlomerulonephritis, IGAGlomerulonephritisSjogren's Syndrome
Global Approved IndicationsGlomerulonephritis, IGA
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/11/25
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesVisterra Inc
China Registration ClassN/A

Develop Information

Active CompaniesOtsuka Pharmaceutical Development & Commercialization IncOtsuka Pharmaceutical Co LtdOtsuka Beijing Research Institute
Inactive CompaniesN/A
Active IndicationsGlomerulonephritis, IGAGlomerulonephritisSjogren's Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A